X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The multicenter ACTIVATE study is designed to evaluate the efficacy, safety, tolerability, PK, and pharmacodynamics of MPH-313 (etigilimab), Mereo’s proprietary anti-TIGIT antibody, in combination with a PD-1 inhibitor, nivolumab, with dosing every two weeks.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 12, 2022
Details:
Treatment of MPH-313 (etigilimab) in combination with nivolumab has shown preliminary efficacy across multiple tumor types with 2 complete responses, 4 partial responses, and 10 stable disease for an ORR of 15.8% and DCR of 42.1% in heavily pre-treated.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
The combination of MPH-313 (etigilimab) and nivolumab has been safe and well tolerated, with an overall response rate (ORR) of 11% and disease control rate (DCR) of 44% with no new safety signals observed to-date.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
Company promising efficacy, safety, and biomarker data from ACTIVATE aims to enroll approximately 125 patients across seven parallel cohorts of anti-TIGIT antibody MPH-313(etigilimab) in combination with nivolumab for recurrent advanced metastatic solid tumors.
Lead Product(s): Etigilimab,Nivolumab
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2021
Details:
Mereo is on track to initiate the Phase 1b/2 basket study in the fourth quarter of 2020. The study will evaluate etigilimab in combination with an anti-PD-1 initially in 100 patients with a defined series of tumor types, including biomarker enriched and rare tumor cohorts.
Lead Product(s): Etigilimab,Anti-PD-1 therapy
Therapeutic Area: Oncology Product Name: MPH-313
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2020
Details:
Along with this private placement, Mereo plans to advance etigilimab (Anti-TIGIT) into a Phase 1b study alongside progressing its rare disease product portfolio, based on the Company’s existing promising clinical data with etigilimab.
Lead Product(s): Etigilimab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: OrbiMed
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
